LBH589 and RAD001
Phase 1UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour
Conditions
Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour
Trial Timeline
Mar 1, 2010 → Dec 1, 2018
NCT ID
NCT01341834About LBH589 and RAD001
LBH589 and RAD001 is a phase 1 stage product being developed by Novartis for Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour. The current trial status is unknown. This product is registered under clinical trial identifier NCT01341834. Target conditions include Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour.
What happened to similar drugs?
0 of 13 similar drugs in Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour were approved
Approved (0) Terminated (0) Active (13)
🔄PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + CapecitabineSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
6
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01341834 | Phase 1 | UNKNOWN |
Competing Products
20 competing products in Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour